-
公开(公告)号:US20100093788A1
公开(公告)日:2010-04-15
申请号:US12576283
申请日:2009-10-09
申请人: Mark R. Player , Daniel J. Parks , William Parsons , Senath K. Meegalla , Carl R. Illig , Shelley K. Ballentine
发明人: Mark R. Player , Daniel J. Parks , William Parsons , Senath K. Meegalla , Carl R. Illig , Shelley K. Ballentine
IPC分类号: A61K31/437 , C07D261/20 , A61K31/42 , C07D498/10 , C07D263/52 , A61K31/421 , C07D471/02 , A61P29/00 , A61P25/24 , A61P9/00
CPC分类号: C07D261/20 , C07D263/52 , C07D403/04 , C07D413/04 , C07D413/14 , C07D471/04 , C07D498/10
摘要: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein W1, W2, W3, R1, R1a, R2, R2a, R3, V, Q, and X are defined herein.
摘要翻译: 公开了用于治疗各种疾病,综合征,病症和障碍(包括疼痛)的化合物,组合物和方法。 这样的化合物由式I表示如下:其中W1,W2,W3,R1,R1a,R2,R2a,R3,V,Q和X如本文所定义。
-
公开(公告)号:US08232409B2
公开(公告)日:2012-07-31
申请号:US12576283
申请日:2009-10-09
申请人: Mark R. Player , Daniel J. Parks , William Parsons , Sanath K. Meegalla , Carl R. Illig , Shelley K. Ballentine
发明人: Mark R. Player , Daniel J. Parks , William Parsons , Sanath K. Meegalla , Carl R. Illig , Shelley K. Ballentine
IPC分类号: A61K31/4188 , A61K31/4184 , A61K31/422 , A61K31/437 , C07D405/00 , C07D413/04 , C07D413/14
CPC分类号: C07D261/20 , C07D263/52 , C07D403/04 , C07D413/04 , C07D413/14 , C07D471/04 , C07D498/10
摘要: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein W1, W2, W3, R1, R1a, R2, R2a, R3, V, Q, and X are defined herein.
摘要翻译: 公开了用于治疗各种疾病,综合征,病症和障碍(包括疼痛)的化合物,组合物和方法。 这样的化合物由式I表示如下:其中W1,W2,W3,R1,R1a,R2,R2a,R3,V,Q和X如本文所定义。
-
公开(公告)号:US07446210B2
公开(公告)日:2008-11-04
申请号:US11257208
申请日:2005-10-24
申请人: Tianbao Lu , Tho V. Thieu , Yu-Kai Lee , Daniel J. Parks , Thomas P. Markotan , Wenxi Pan , Karen L. Milkiewicz , Mark R. Player
发明人: Tianbao Lu , Tho V. Thieu , Yu-Kai Lee , Daniel J. Parks , Thomas P. Markotan , Wenxi Pan , Karen L. Milkiewicz , Mark R. Player
IPC分类号: C07D207/00 , C07D213/00 , C07D231/00 , C07D231/54 , C07D239/02 , C07D241/04 , C07D265/28 , C07D295/00 , C07D487/00
CPC分类号: C07D413/14 , C07D231/56 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D409/14 , C07D413/04 , C07D417/10
摘要: The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.
摘要翻译: 本发明涉及式I的新型化合物及其形式和药物组合物,以及其作为因子Xa抑制剂的用途。
-
公开(公告)号:US07612211B2
公开(公告)日:2009-11-03
申请号:US11954647
申请日:2007-12-12
IPC分类号: A61K31/4184 , C07D235/12
CPC分类号: C07D235/12 , C07D235/06 , C07D235/14 , C07D235/26 , C07D235/30 , C07D401/12 , C07D405/12
摘要: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
摘要翻译: 本发明涉及式(I)的化合物:含有这些化合物的药物组合物和使用它们的治疗方法。
-
公开(公告)号:US20080146637A1
公开(公告)日:2008-06-19
申请号:US11954647
申请日:2007-12-12
IPC分类号: A61K31/4184 , A61P29/00 , C07D235/12
CPC分类号: C07D235/12 , C07D235/06 , C07D235/14 , C07D235/26 , C07D235/30 , C07D401/12 , C07D405/12
摘要: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
摘要翻译: 本发明涉及式(I)的化合物:含有这些化合物的药物组合物和使用它们的治疗方法。
-
公开(公告)号:US07115598B2
公开(公告)日:2006-10-03
申请号:US10829040
申请日:2004-04-21
申请人: Tianbao Lu , Karen L. Milkiewicz , Pierre Raboisson , Maxwell David Cummings , Raul R. Calvo , Daniel J. Parks , Louis V. Lafrance, III , Juan Jose Marugan Sanchez , Joan Gushue , Kristi Leonard
发明人: Tianbao Lu , Karen L. Milkiewicz , Pierre Raboisson , Maxwell David Cummings , Raul R. Calvo , Daniel J. Parks , Louis V. Lafrance, III , Juan Jose Marugan Sanchez , Joan Gushue , Kristi Leonard
IPC分类号: C07D243/14 , A61K31/55
CPC分类号: C07D243/14
摘要: The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R1, R2, R9, R10, Ra, Rd and M are defined herein;X is a bivalent radical of: an alkane, a cycloalkane, an optionally-substituted arene, an optionally-substituted heteroarene, an optionally-substituted arylalkane or an optionally-substituted heteroarylalkane; andR3 is —CO2Rd, —CO2M, —OH, —NHRd, —SO2Rd, —NHCONHRd, optionally-substituted amidino or optionally-substituted guanidino;or R3—X— is hydrogen or an electron pair;R4 is oxygen or —NR9R10;R5 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; andR6, R7 and R8 are independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkylalkyl, aralkyl or heteroarylalkyl, each of which is optionally substituted; or R6 and R7, together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted 1 to 3 times with Ra.
摘要翻译: 本发明涉及新的1,4-二氮杂,其药物组合物及其作为HDM2-p53相互作用抑制剂的用途。 化合物具有式I:或其溶剂合物,水合物或其药学上可接受的盐; 其中:R 1,R 2,R 9,R 10,R a, >,R d和M在本文中定义; X是二价基团:烷烃,环烷烃,任选取代的芳烃,任选取代的杂芳烃,任选取代的芳基烷烃或任选取代的杂芳基烷烃; 和R 3是-CO 2 R 2,-CO 2 M,-OH,-NHR 0 任选取代的脒基或任选取代的胍基;其中R 1,R 2,R 3,R 4, 或R 3 -X-是氢或电子对; R 4是氧或-NR 9 R 10; R 5是环烷基,芳基,杂芳基,环烷基烷基,芳烷基,杂芳基烷基或饱和或部分不饱和的杂环,其各自任选被取代; R 6和R 8独立地是氢,烷基,环烷基,芳基,杂芳基,饱和或部分不饱和的杂环,环烷基烷基 ,芳烷基或杂芳基烷基,其各自任选被取代; 或R 6和R 7与它们所连接的碳原子一起形成3-至7-元碳环,任选地被R 1取代1至3倍, SUP> a SUP>。
-
-
-
-
-